Data as of Jul 24
| +0.07 / +3.59%|
The 2 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 7.50, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +271.29% increase from the last price of 2.02.
The current consensus among 4 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.